



RECEIVED

FORM PTO-449 (Modification)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1155.005	Serial No.: 09/001,039 MAY 21 2001
INFORMATION DISCLOSURE CITATION		Applicants: Doug Jolly et al.	
(Use several sheets if necessary)		Filing Date: 12/30/97	TECH CENTER 1600/2900 Group: 1636

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
	BA	✓ WO 92/05266	04/02/92	PCT				
	BB	✓ WO 92/14829	09/03/92	PCT				
	BC	✓ WO 95/16582	06/22/95	PCT			X (abstract only)	
	BD							
	BE							

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

121	CA	✓ Lynch and Miller, "Production of High-Titer Helper Virus-Free Retroviral Vectors by Co-cultivation of Packaging Cells with Different Host Ranges" <u>J. Virology</u> 65(7):3887-3890, July, 1991
122	CB	✓ Corser et al., "Use of Helper Cells with Two Host Ranges to Generate High-Titer Retroviral Vectors" <u>Virology</u> 193:385-395, 1993
123	CC	✓ Chouh et al., "Development and Analysis of Retroviral Vectors Expressing Human Factor VIII as a Potential Gene Therapy for Hemophilia A" <u>Human Gene Therapy</u> 6 1363-1377, November, 1995
124	CD	✓ Faullux et al., "State and Prospects of Gene Therapy for the Hemophilias" <u>Thrombosis and Haemostasis</u> 74(1):263-273, July, 1995
125	CE	✓ Brownlee, "Prospects for Gene Therapy of Haemophilia A and B" <u>British Medical Bulletin</u> 52 (1):91-105, 1995
126	CF	✓ Toole et al., "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor" <u>Nature</u> 311:342-347, November, 1994
Examiner <i>[Signature]</i>		Date Considered 6/2/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.